Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer – Xconomy
Xconomy |
Merck Immunotherapy Drug Notches Another FDA Win in Lung Cancer
Xconomy The FDA approval for (NYSE: MRK) pembrozlizumab (Keytruda) to treat metastatic nonsquamous non-small cell lung cancer widens the use of the immunotherapy. Last year, the FDA approved it for lung cancer patients whose tumors produce a high amount … US FDA approves Merck immunotherapy/chemo combo for lung cancerReuters Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy ApprovalTheStreet.com Why Merck’s Keytruda Just Became a Lung Cancer Game ChangerFortune Channel NewsAsia –Business Wire –Merck Newsroom all 60 news articles » |
Men’s Health |
This Gun Sprays Stem Cells, Helps Burn Victims Grow Skin in Days
Men’s Health A revolutionary new technique is enabling burn victims to heal quicker, less painfully, and with more normal skin. And it’s all thanks to a gun. The SkinGun sprays stem cells onto wounds and allows patients to grow a new, healthy layer of skin in as … |
Immuno-Oncology News |
Inovio, Regeneron Plan Clinical Trial of Triple-Combo Immunotherapy for Brain Tumors
Immuno-Oncology News Patients with a newly diagnosed glioblastoma multiforme (GBM) brain tumor will be able to enroll soon in a Phase 1b/2a clinical trial of a triple-combination immunotherapy for the cancer. Inovio Pharmaceuticals will conduct the study to evaluate its T … Regeneron and Inovio to aim immunotherapy at hard-to-treat brain tumourpharmaphorum Inovio (INO) Q1 Loss Narrower Than Expected, Revenues BeatNasdaq Inovio Pharmaceuticals Reports 2017 First Quarter Financial ResultsP&T Community pharmabiz.com all 85 news articles » |